Journal of hepatology
Individualising endpoints in chronic HBV treatment: HBsAg loss and beyond.
Milan J Sonneveld, Harry L A Janssen
Published: 202510.1016/j.jhep.2025.12.006
Abstract
There are many new compounds in development for the treatment of chronic hepatitis B (CHB). Although major on-treatment declines in hepatitis B surface antigen (HBsAg) can be achieved with some of these drugs, achieving sustained post-treatment HBsAg…
Preview only. Read the full abstract at the source